U.S. stock market midday update: BridgeBio's stock price soared 10.67%, trading volume surged, and sector trends have attracted market attention?

U.S. Stock Market Midday Update BridgeBio Oncology Therapeutics, up 10.67%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry AbbVie down 3.65%. Based on recent key news: On January 9, AbbVie released its fourth-quarter and fiscal year 2025 adjusted earnings per share guidance, leading to a decline in stock price. Wolfe Research downgraded its rating from outperform to market perform, raising concerns about its profitability. On January 8, AbbVie announced it would incur $1.3 billion in R&D expenses, impacting its fourth-quarter earnings per share, putting pressure on the stock price. The company expects fourth-quarter earnings per share to be between $2.61 and $2.65, below market expectations. On January 8, market rumors suggested that AbbVie is in deep discussions to acquire Revolution Medicines, with a deal value potentially exceeding $20 billion. Although the company denied the negotiations, the related news triggered stock price fluctuations. The biotechnology industry is facing consolidation pressures, with active capital flow. Revolution Medicines up 3.83%. Based on recent key news: On January 8, AbbVie is in deep negotiations to acquire Revolution Medicines, with a deal value potentially exceeding $20 billion. This news drove Revolution's stock price up by about 30%, leading to multiple volatility trading halts. Source: The Wall Street Journal On January 8, Revolution Medicines announced that its drug Zoldonrasib received FDA breakthrough therapy designation, further boosting market confidence in its R&D capabilities, resulting in a stock price increase. Source: Reuters On January 8, analyst Laura Prendergast stated that Revolution Medicines' management had indicated the company plans to remain independent, but acquisition rumors have significantly boosted its stock price. She believes the company could be acquired, with a valuation potentially exceeding $30 billion. Source: Barron's The biotechnology industry has seen active trading recently, with increased risks. Regeneron Pharmaceuticals down 0.98%. Based on recent key news: On January 8, Bank of America Securities upgraded Regeneron Pharmaceuticals' rating from "underperform" to "buy," raising the target price from $627 to $860. Analysts are optimistic about the sales prospects of Eylea HD and Dupixent, expecting Eylea HD sales to exceed market expectations, driving the stock price up On January 8, analysts pointed out that the White House's "Most Favored Nation" agreement could eliminate market uncertainty and further support stock prices. This agreement is expected to lower drug prices and enhance the company's profitability. On January 7, Regeneron Pharmaceuticals' short interest was below the industry average, indicating increased market confidence in the stock, which may provide support for its price. The biotechnology sector has performed strongly recently, with noticeable capital inflows. Stocks ranked at the top of the industry by market capitalization Amgen fell 3.20%. Based on recent key news: On January 7, UBS upgraded Amgen's rating to "Buy," raising the target price to $380, expecting its two pipeline drugs to drive company growth through 2030. This move provides upward potential for the stock price. On January 6, Amgen announced the acquisition of UK cancer drug developer Dark Blue for $840 million, aiming to expand its oncology product line and enhance its research in targeted protein degradation. On January 6, Amgen announced its acquisition plan, further solidifying its position in leukemia treatment and driving stock price volatility. Competition in the biotechnology sector is intensifying, with significant policy impacts